BASIC DIAGNOSTIC TESTING

PROTOCOLS FOR LEVEL A LABORATORIES

FOR THE PRESUMPTIVE IDENTIFICATION OF

*Bacillus anthracis*

CDC
Centers for Disease Control and Prevention

ASM
American Society for Microbiology

APHL
Association of Public Health Laboratories
Credits: *Bacillus anthracis*

**Subject Matter Experts, ASM**

James W. Snyder, Ph.D.
University of Louisville, School of Medicine

Daniel S. Shapiro, M.D.
Boston Medical Center

Mary J. R. Gilchrist, Ph.D.
University of Iowa

**Subject Matter Experts, CDC**

Robbin S. Weyant, Ph.D.
Centers for Disease Control and Prevention

Tanja Popovic, M.D., Ph.D.
Centers for Disease Control and Prevention

**Subject Matter Expert, USAMRIID**

John W. Ezzell, Jr., Ph.D.
United States Army Medical Research Institute of Infectious Diseases

**Technical Editor**

Stephen A. Morse, M.S.P.H., Ph.D.
Centers for Disease Control and Prevention
Table of Contents: *Bacillus anthracis*

I. General information  
   A. Description of organism  
   B. History  
   C. Geographic distribution  
   D. Clinical presentation

II. Procedures  
   A. General  
   B. Precautions  
   C. Specimens  
      1. Acceptable specimens  
      2. Rejection criteria  
      3. Specimen transport and storage  
   D. Materials  
   E. Quality control  
   F. Stains and smears: Gram stain  
   G. Cultures  
      1. Inoculation and plating procedure  
      2. Incubation  
      3. Colony characteristics  
   H. Motility test  
      1. Purpose  
      2. Wet mount procedure  
      3. Motility medium test  
      4. Interpretation of results  
      5. Quality control  
      6. Resolving out-of-control results  
   I. Interpretation and reporting  
      1. Presumptive identification criteria  
      2. Reporting/action

III. References

IV. Appendix:  
   A. India ink stain  
   B. Nasal specimens for screening  
   C. Change record
I. General information

A. Description of organism

*Bacillus anthracis* is an aerobic, spore-forming, nonmotile, large, gram-positive rod.

B. History

The first recorded description of anthrax is in the Book of *Genesis*, wherein the disease was referred to as the fifth plague (1491 BC) and was responsible for killing Egyptian cattle. Additional descriptions of anthrax affecting both animals and humans have been recorded in the early literature of Hindus, Greeks, and Romans. A pandemic, referred to as the “black bane,” swept through Europe in the 17th century and was responsible for many animal and human deaths. The human form of disease was later referred to as the “malignant pustule.”

During the 19th century, several distinguished microbiologists characterized the pathologic basis of the disease and attempted to develop a vaccine to combat the problem of anthrax in the livestock industry. The first field-tested vaccine, developed by Pasteur in 1881 as an attenuated spore vaccine, was followed in 1939 by Sterne’s development of a vaccine consisting of a spore suspension of an avirulent, nonencapsulated live strain of *B. anthracis*. The vaccine remains in use today for the vaccination of livestock.

The first reports of outbreaks associated with occupational cutaneous and respiratory anthrax occurred in the mid-1800s in the industrialized parts of Europe, namely England and Germany. Cutaneous forms of the disease resulted from handling hides, wool, and hair; aerosol-creating activities such as carding wool (“woolsorter’s disease”) or handling contaminated sacks of dried bones in the production of bonemeal were responsible for the respiratory form of the disease. Early in the 20th century, in the United States, anthrax occurred in individuals who handled materials that had been woven from contaminated animal fibers. Since that time, the number of reported cases in developed countries has steadily declined. This decline can be attributed to the administration of a cell-free anthrax vaccine in individuals who work in a high-risk industry, a decrease in importation of potentially contaminated animal products, improved animal husbandry, and the emphasis placed on the practice of hygiene in industry.

C. Geographic distribution

Although anthrax can be found globally in temperate zones, it is more often a risk in countries with less standardized and less effective public health programs. Areas currently listed as high risk are South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. Anthrax infrequently occurs in livestock and wildlife in North America; however, anthrax outbreaks have been reported among deer from Texas and among wood buffalo in the Northwest Territory in Canada. Animal infections in the United States are reported most often in Texas and North and South Dakota.
D. Clinical presentation

Humans can become infected with *B. anthracis* by handling products or consuming undercooked meat from infected animals. Infection may also result from inhalation of *B. anthracis* spores from contaminated animal products, such as wool, or the intentional release of spores. Human-to-human transmission has not been reported. Three forms of anthrax occur in humans: cutaneous, gastrointestinal, and inhalational.

1. **Cutaneous anthrax:** Cutaneous infections occur when the bacterium or spore enters a cut or abrasion on the skin. Skin infection begins as a raised itchy bump or papule that resembles an insect bite. Within 1 to 2 days, the bump develops into a fluid-filled vesicle, which ruptures to form a painless ulcer (called an eschar), usually 1 to 3 cm in diameter, with a characteristic black necrotic (dying) area in the center. Pronounced edema is often associated with the lesions because of the release of edema toxin by *B. anthracis*. Lymph glands in the adjacent area may also swell. Approximately 20% of untreated cases of cutaneous anthrax result in death either because the infection becomes systemic or because of respiratory distress caused by edema in the cervical and upper thoracic regions. Deaths are rare following appropriate antibiotic therapy, with lesions becoming sterile within 24 h and resolving within several weeks.

2. **Gastrointestinal anthrax:** The gastrointestinal form of anthrax may follow the consumption of contaminated meat from infected animals and is characterized by an acute inflammation of the intestinal tract. Initial signs of nausea, loss of appetite, vomiting, and fever are followed by abdominal pain, vomiting of blood, and severe bloody diarrhea. The mortality rate is difficult to determine for gastrointestinal anthrax, but is estimated to be 25 to 60% if not treated.

3. **Inhalational anthrax:** Inhalational anthrax results from inhaling *B. anthracis* spores and is most likely following an intentional aerosol release of *B. anthracis*. After an incubation period of 1 to 6 days (depending on the number of inhaled spores), disease onset is gradual and nonspecific. Fever, malaise, and fatigue may be present initially, sometimes in association with a nonproductive cough and mild chest discomfort. These initial symptoms are often followed by a short period of improvement (ranging from several hours to days), followed by the abrupt development of severe respiratory distress with dyspnea (labored breathing), diaphoresis (perspiration), stridor (high-pitched whistling respiration), and cyanosis (bluish skin color). Shock and death usually occur within 24 to 36 h after the onset of respiratory distress, and in later stages, mortality approaches 100% despite aggressive treatment. Physical findings are usually nonspecific. The chest X-ray is often pathognomonic (disease-specific), revealing a widened mediastinum with pleural effusions, but typically without infiltrates.
II. Procedures: *Bacillus anthracis*

A. General: The procedures described below function to rule out or presumptively identify *B. anthracis* from clinical specimens or isolates.

B. Precautions: These procedures should be performed in microbiology laboratories that use Biological Safety Level-2 (BSL-2) practices.

C. Specimens

1. Acceptable specimens: Collect other specimens if/as clinically indicated (e.g., cerebrospinal fluid [CSF], lymph node biopsy). Refer to Appendixes for information on nasal specimens for screening.

   a. Cutaneous anthrax
      (1) Vesicular stage: Aseptically collect vesicular fluid on sterile swabs from previously unopened vesicles. Note: The anthrax bacilli are most likely to be seen by Gram stain in the vesicular stage.
      (2) Eschar stage: Collect eschar material by carefully lifting the eschar’s outer edge; insert a sterile swab, then slowly rotate for 2-3 sec beneath the edge of the eschar without removing it.

   b. Gastrointestinal anthrax
      (1) Blood cultures: Collect appropriate blood volume and number of sets per laboratory protocol. In later stages of disease (2-8 days post-exposure) blood cultures may yield the organism, especially if obtained before antibiotic treatment.
      (2) Stool: Transfer ≥5 g of stool directly into a clean, dry, sterile, wide-mouth, leak-proof container.
      (3) Rectal swab: For patients unable to pass a specimen, obtain a rectal swab by carefully inserting a swab 1 inch beyond the anal sphincter.

   c. Inhalational anthrax
      (1) Blood cultures: Collect appropriate blood volume and number of sets per laboratory protocol.
      (2) Sputum: Collect >1 ml of a lower respiratory specimen into a sterile container. Inhalational anthrax usually does not result in sputum formation.

2. Rejection criteria: Use standard laboratory criteria.

3. Specimen transport and storage: Refer to Shipping Procedure.
   a. Swabs: Transport directly to laboratory at room temperature. For transport time >1 h, transport at 2-8°C.
   b. Stool: Transport unpreserved stool to laboratory within 1 h. For transport time >1 h, transport at 2-8°C.
   c. Sputum: Transport in sterile, screw-capped container at room temperature when transport time is <1 h. For transport time >1 h, transport at 2-8°C.
d. Blood culture: Transport directly to laboratory at room temperature.

D. Materials

1. Reagents
   a. Gram stain reagents
   b. Catalase reagent (3% hydrogen peroxide)
   c. Motility media (or slide, coverslips, saline for wet mount)
   d. Sterile saline
   e. India ink (an optional test, refer to Appendix)

2. Media
   a. 5% sheep blood agar (SBA) or equivalent
   b. Chocolate agar (CA)
   c. MacConkey agar (MAC)
   d. Phenyl ethyl alcohol agar (PEA)
   e. Blood culture bottles
   f. Tubed motility media
   g. Tryptic soy broth (TSB), or equivalent
   h. Thioglycolate broth or equivalent

3. Equipment/miscellaneous
   a. Blood culture instrument (optional)
   b. Light microscope with 10X, 40X and 100X objectives and 10X eyepiece
   c. Microscope slides and coverslips
   d. Disposable bacteriologic inoculating loops
   e. Incubator, 35-37°C, ambient preferred (CO₂ enriched is acceptable)

E. Quality control: Document all quality control results for the following tests per standard laboratory procedure/protocol.

F. Stains and smears: Gram stain

2. Interpretation
   a. *B. anthracis* is a large gram-positive rod (1-1.5 X 3-5 µm).
   b. Blood and impression smears: Vegetative cells seen on Gram stain of blood and
      impression smears are in short chains of 2-4 cells that are encapsulated, which may be
      seen on the Gram stain as clear zones around the bacilli. Spores are not present in
      clinical samples unless exposed to low CO₂ levels, such as those found in ambient
      atmosphere; higher CO₂ levels within the body inhibit sporulation. The presence of
      large encapsulated gram-positive rods in the blood is strongly presumptive for *B.
      anthracis* identification. Refer to Fig. A2.
   c. Growth on SBA or equivalent medium: *B. anthracis* forms oval, central-to-subterminal
      spores (1 X 1.5 µm) on SBA that do not cause significant swelling of the cell;
      frequently occur as long chains of bacilli. However, cells from growth on SBA
regardless of the incubation conditions (ambient atmosphere or CO₂ enriched) are not encapsulated. Refer to Fig. A3a and Fig. A3b.

G. Cultures

1. Inoculation and plating procedure: Inoculate and streak the following media for isolation of the respective specimen types. Note: Standard media should be used according to normal laboratory procedures.
   b. Cutaneous swab specimens: Plate directly on media used routinely for surface wounds such as SBA, MAC, and broth enrichment, and prepare smears for staining. Note: *B. anthracis* does not grow on MAC.
   c. Stool: Plate directly on appropriate media, such as PEA, SBA, and MAC.
   d. Sputum specimens: Plate directly on media used routinely, such as SBA, MAC, and CA, and prepare smears for staining.

2. Incubation
   a. Temperature: 35-37°C
   b. Atmosphere: Ambient preferred, CO₂ is acceptable.
   c. Length of incubation: Hold primary plates for at least 3 days; read daily. Examine plates within 18-24 h of incubation. Growth of *B. anthracis* may be observed as early as 8 h after incubation.

3. Colony characteristics of *B. anthracis*
   a. After incubation of SBA plates for 15-24 h at 35-37°C, well isolated colonies of *B. anthracis* are 2-5 mm in diameter. The flat or slightly convex colonies are irregularly round, with edges that are slightly undulate (irregular, wavy border), and have a ground-glass appearance. There may be often comma-shaped projections from the colony edge, producing the "Medusa-head" colony. Refer to Fig. A4.
   b. *B. anthracis* colonies on SBA usually have a tenacious consistency. When teased with a loop, the growth will stand up like beaten egg white; refer to Fig. A5. In contrast to colonies of *B. cereus* and *B. thuringiensis*, colonies of *B. anthracis* are not β-hemolytic; refer to Fig. A6. However, weak hemolysis may be observed under areas of confluent growth in aging cultures and should not be confused with β-hemolysis.
   c. When examining primary growth media, it is important to compare the extent of growth on SBA plates with that on MAC. *B. anthracis* grows well on SBA but does not grow on MAC.
   d. *B. anthracis* grows rapidly; heavily inoculated areas may show growth within 6-8 h and individual colonies may be detected within 12-15 h. This trait can be used to isolate *B. anthracis* from mixed cultures containing slower-growing organisms.

H. Motility test: Wet mount or motility medium

1. Purpose: Used to determine motility of suspected isolates. *B. anthracis* is nonmotile. Two methods are given, the wet mount and the motility medium test.
2. **Wet mount procedure**
   a. Deliver 2 drops (approximately 0.1 ml) of TSB, or equivalent, into a sterile glass tube. Using an inoculating loop, transfer a portion of the suspect colony from a 12-20 h culture and suspend the growth in the broth medium.
   b. Alternatively, a loopful of medium from a fresh broth culture can be used.
   c. Transfer 10 µl of the suspension to a microscope slide and overlay with a coverslip.
   d. Examine slide under a microscope using the 40X objective (total magnification 400X; may also be viewed at 1000X with oil objective).
   e. Discard slide(s) following standard laboratory procedures, such as into 0.5% hypochlorite solution.

3. **Motility medium test procedure**
   a. Using a sterile inoculating needle, remove a portion of growth from an isolated, suspect colony after 18-24 h incubation.
   b. Inoculate the motility medium by carefully stabbing the needle 3-4 cm into the medium and then drawing the needle directly back out so that a single line of inoculum can be observed.
   c. Incubate the tube at 35-37°C in ambient atmosphere for 18-24 h.

4. **Interpretation of motility results:** Lack of motility is unusual among *Bacillus* spp. and is therefore useful in the preliminary identification of *B. anthracis* isolates.
   a. **Wet mount**
      (1) Positive result: Motile organisms will be observed moving throughout the suspension. Observe that the movement may be sluggish/slower than that of the positive controls.
      (2) Negative result: Nonmotile organisms either do not move or move with Brownian motion.
   b. **Motility test**
      (1) Positive result: Motile organisms will form a diffuse growth zone around the inoculum stab.
      (2) Negative result: Nonmotile organisms, such as *B. anthracis*, will form a single line of growth that does not deviate from the original inoculum stab.

5. **Quality control**
   a. Positive control strain: *Pseudomonas aeruginosa* ATCC 35032 or laboratory-validated equivalent will demonstrate motility.
   b. Negative control strain: *Acinetobacter* spp. ATCC 49139 or laboratory-validated equivalent will show no motility.
   c. Method controls: Perform the test with fresh cultures of the control strains using the same method as with unknowns. Control strains should be assayed on each day of testing.

6. **Resolving out-of-control results**
   a. Check media, reagents, controls and equipment; replace or correct as appropriate. Document corrective actions and repeat test.
   b. Check purity and identity of control strains and repeat testing.
I. Interpretation and reporting

1. Presumptive identification criteria: Refer to Table A1.
   a. Direct smears from clinical samples, such as blood, CSF, or skin lesion (eschar) material: Encapsulated gram-positive rods
   b. From growth on SBA or equivalent media: Large gram-positive rods (may stain gram-variable after 72 h of culture). Spores may be found in culture, under non-CO\textsubscript{2} atmosphere (but not on direct examination). Spores do not swell the cell and are oval-shaped.
   c. Rapid, aerobic growth, and tenacious colonies on sheep blood agar.
   d. Catalase positive
   e. Nonmotile: In addition to \textit{B. anthracis}, \textit{B. cereus} var. mycoides is nonmotile.
   f. Nonhemolytic on SBA, ground-glass appearance of colonies

2. Rule out: While hemolysis, gram stain morphology, or motility can be used for rule out when the result provides clear evidence that the isolate is not \textit{B. anthracis} (e.g., a clearly visible zone of beta hemolysis), a combination of two Level A tests is recommended for rule out.

3. Reporting/action
   a. Consult with state public health laboratory director (or designate) if \textit{B. anthracis} is suspected.
   b. General instruction and information
      (1) Preserve original specimens pursuant to a potential criminal investigation and possible transfer to an appropriate LRN laboratory.
      (2) Environmental/nonclinical samples and samples from announced events are not processed by Level A Laboratory; submitter should contact the state public health laboratory directly.
      (3) The state public health laboratory/state public health department will coordinate notification of local FBI agents as appropriate.
      (4) Assist local law enforcement efforts in conjunction with guidance received from the state public health laboratory.
      (5) The state public health laboratory/state public health department may request transfer of suspicious specimens prior to presumptive testing.
      (g) FBI and state public health laboratory/state public health department will coordinate the transfer of isolates/specimens to a higher-level LRN laboratory as appropriate; refer to Shipping Procedure.
   c. Immediately notify state public health laboratory director (or designate) and state public health department epidemiologist/health officer if \textit{B. anthracis} cannot be ruled out and a bioterrorist event is suspected.
   d. Immediately notify physician/infection control according to internal policies if \textit{B. anthracis} cannot be ruled.
   e. If \textit{B. anthracis} is ruled out, proceed with efforts to identify using established procedures.
III. References


**Bacillus anthracis**: Level A laboratory flowchart

Morphology: Large aerobic, gram positive rods (1 to 1.5 by 3 to 5 μm)
Smears/blood/CSF: Short chains of 2-4 cells that appear encapsulated
Sheep blood agar (ambient atmosphere): Oval, central-to-subterminal spores which do not cause significant swelling of cell; often in long chains

Growth on sheep blood agar: 2-5 mm, tenacious, nonhemolytic colonies after 15-24 h (flat/slightly convex, irregularly round colonies with irregular/wavy border and ground glass appearance)

Perform all additional work in biosafety cabinet

Hemolysis: Negative
Catalase: Positive
Motility: Nonmotile

**No** (features not present)
Report: *Bacillus* species, NOT *B. anthracis*; continue identification per laboratory procedures

**Yes** (features present)
Report: *Bacillus* species, sent to reference laboratory to rule out *B. anthracis*

**Figure A1**: Level A flowchart for *Bacillus anthracis*
Figure A2. Gram stain of *B. anthracis* in rhesus monkey blood, magnification 1000X
Figure A3a. Gram stain of *B. anthracis* from SBA, magnification 1000X
Figure A3b. Gram stain of *B. anthracis* with spores, magnification 1000X
Figure A4. *B. anthracis* colony morphology; overnight cultures on SBA
Figure A5. Tenacious colonies of *B. anthracis* on SBA
**Figure A6.** *B. anthracis* and *B. cereus* colony morphology; overnight cultures of *B. cereus* (left side of plate) and *B. anthracis* (right side) on SBA.
**Table A1.** Presumptive identification of *Bacillus anthracis*

<table>
<thead>
<tr>
<th>Lab Level</th>
<th>Type of sample</th>
<th>Presumptive identification</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Clinical sample</td>
<td>1. Gram-positive rods AND 2. Capsule</td>
<td>Gram stain</td>
</tr>
</tbody>
</table>
IV. Appendices

A: Appendix A: India ink stain

1. **Purpose:** This optional test is used to improve visualization of encapsulated *B. anthracis* in clinical samples such as blood, blood culture bottles, or cerebrospinal fluid (CSF). This is not an ASM recommended procedure; performance of the test requires staff that are trained/experienced with this procedure.

2. **Quality control**
   a. Positive control strain: *Klebsiella pneumoniae* (or laboratory validated equivalent) will demonstrate a well-defined clear zone on SBA.
   b. Negative control strain: *E. coli* ATCC 25922 (or laboratory validated equivalent) will demonstrate no clear zone.
   c. Method controls: Perform the test with suspensions of fresh cultures of the control strains. Control strains should be assayed on each day of testing.
   d. Resolving out-of-control results: Check media, reagents, controls and equipment; replace or correct as appropriate. Document corrective actions and repeat test.

3. **Procedure**
   a. For the controls, transfer a small amount of growth (1 mm diameter) from each control SBA plate (positive control = *Klebsiella pneumoniae*; negative control = *Escherichia coli* ATCC 25922) into 0.5 ml saline and mix.
   b. For the unknowns, take 100 µl of sample (blood, CSF). Transfer 5-10 µl of unknown sample or control to a slide. Place a coverslip on the drop, and then add 5-10 µl of India ink to the edge of the coverslip. After the ink diffuses across the slide, view the cells using 100X oil immersion objective with oil on top of the coverslip.

4. **Interpretation**
   a. Positive result: The capsule will appear as a well-defined clear zone around the cells.
   b. Negative result: No zone will be present.

5. **Reporting/actions**
   a. Clinical specimens with encapsulated (visualized with India Ink), gram-positive rods provide a presumptive identification of *B. anthracis*; it does not confirm *B. anthracis*.
   b. Every effort should be made to obtain an isolate for continued testing and referral to state public health laboratory.

6. **Limitations**
   a. Interpretation of results requires trained/experienced staff.
   b. A negative test result should not be used to rule out *B. anthracis*. 
B. Appendix B: Nasal specimens for screening *Bacillus anthracis*

1. **General:** Nasal specimens (nares culture) should ONLY be used to support a confirmed exposure to *B. anthracis* or during an ongoing epidemiologic investigation. Gram stain of nasal specimens for *B. anthracis* spores are not recommended. Refer to limitations section below.

2. **Materials:** Swab (Dacron, rayon or other synthetic swabs are preferred over cotton) and transport medium for culture.

3. **Procedure**
   a. **Selection**
      (1) The specimen of choice is a swab specimen taken at least 1 cm inside the nares.
      (2) Lesions in the nose require samples from the advancing margin of the lesions.
   b. **Method**
      (1) Carefully insert the moistened swab (saline, sterile water) at least 1 cm into the nares.
      (2) Firmly sample the inside of the nares by rotating the swab and leaving it in place for 10 to 15 sec.
      (3) Withdraw the swab, insert it into its transport container, and submit the sampling unit to the laboratory for culture.
   c. **Labeling**
      (1) Label the swab container with patient information.
      (2) Indicate, if possible, the degree or likelihood of exposure.
   d. **Transport**
      (1) Transport the specimen to the laboratory as soon as possible.
      (2) Do not refrigerate specimens for culture.
   e. **Culture: Heat Shock**
      (1) Remove the swab from transport container and place it into 1.5 ml of sterile saline or a nutrient broth such as trypticase soy broth, brain heart infusion broth, or equivalent. Vigorously twist the swab, and recap the tube.
      (2) Leave the swab in the tube. Place the broth suspension into a 65°C water bath for 30 min.
      (3) Plate 100-200 µl of broth on 5% sheep blood agar plate and incubate at 35-37°C for 18-24 h. Many *B. anthracis* will have visible growth in 12-18 h. Observe for characteristics of *B. anthracis*.

4. **Interpretation:** Observe colony morphology for typical *Bacillus* colonies, look for lack of hemolysis, perform Gram stain, and evaluate for *B. anthracis* characteristics as described in the Level A laboratory protocol.

5. **Reporting:** If *B. anthracis* cannot be ruled out, submit the isolate to the state public health laboratory/department for confirmation. Refer to Level A reporting section.

6. **Limitations:** Nasal cultures taken to evaluate for the presence of anthrax spore have not been evaluated for sensitivity or specificity. Nasopharyngeal and throat
specimens are not recommended for anthrax screens and should not be submitted. Nasal cultures are NOT recommended for screening those who are asymptomatic and without known exposure.

7. Procedure Notes
   a. Anterior nares cultures, without an indication of the presence of a lesion, are routinely examined only for presence of *Staphylococcus aureus* and β-hemolytic streptococci. Because of the unknown sensitivity of this method for detecting *B. anthracis* spores, interpret negative results with caution.
   b. Anterior nares cultures cannot be used to predict a subsequent infection with *B. anthracis*, and should not be submitted in lieu of blood and other appropriate specimens from symptomatic patients.
   c. Anaerobic cultures are not done on nasal specimens. *B. anthracis* produces spores in culture only when grown in air.
   d. Nasal swabs may also be plated directly onto sheep blood agar prior to or without heat shocking, however normal nasal flora may overgrow very low numbers of *Bacillus* colonies.
   e. Pediatric needs: Use the same procedure substituting a small fine-wire or nasopharyngeal swab to sample the anterior nares.

C. Appendix C: Change record

1. **18 Mar. 2002** (ban.asm.cp.la.021402)
   a. Recommend use of TSB, or equivalent, for wet mount procedure (II. H. 2. a.)
   b. Added criteria for rule out at Level A (II. I. 2.)

2. **06 Nov. 2001** (ban.asm.cp.la.110501)
   a. Figure A1 and text (II. F. 2. c.) revised to state “frequently” occur as long chains of bacilli.
   b. File name, date, page information added to footer.
   c. Change record added to appendices

3. **29 Oct. 2001** (ban.asm.cp.la.102901f)
   a. Nasal swab procedure added.
   b. File name, date, page information deleted from footer (an error).